The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 1 May 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 225K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kruse, M.
Right arrow Articles by Hauber, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kruse, M.
Right arrow Articles by Hauber, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/5/1581/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 9, May 1, 2000 1581-1590

Original Article

Inhibition of CD83 Cell Surface Expression during Dendritic Cell Maturation by Interference with Nuclear Export of CD83 mRNA

Monika Krusea, Olaf Rosoriusb, Friedrich Krätzerb, Dorian Bevecc, Christine Kuhnta, Alexander Steinkasserera, Gerold Schulera, and Joachim Hauberb
a Department of Dermatology, University Erlangen-Nürnberg, D-91054 Erlangen, Germany
b Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg, D-91054 Erlangen, Germany
c Department of Immunology, Novartis Research Institute, A-1235 Vienna, Austria

Correspondence to: Joachim Hauber, Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg, Schlossgarten 4, D-91054 Erlangen, Germany. Tel:49-9131-85-26182 Fax:49-9131-85-22101 E-mail:jmhauber{at}viro.med.uni-erlangen.de.

Dendritic cells (DCs), nature's adjuvant, must mature to sensitize T cells. However, although the maturation process is essential, it is not yet fully understood at the molecular level. In this study, we investigated the course of expression of the unique hypusine-containing protein eukaryotic initiation factor 5A (eIF-5A), which is part of a particular RNA nuclear export pathway, during in vitro generation of human DCs. We show that eIF-5A expression is significantly upregulated during DC maturation. Furthermore, an inhibitor of the hypusine modification, GC7 (N1-guanyl-1,7-diaminoheptane), prevents CD83 surface expression by apparently interfering with nucleocytoplasmic translocation of the CD83 mRNA and, importantly, significantly inhibits DC-mediated T lymphocyte activation. The data presented suggest that CD83 mRNA is transported from the nucleus to the cytoplasm via a specific nuclear export pathway and that hypusine formation appears to be essential for the maturation of functional DCs. Therefore, pharmacological interference with hypusine formation may provide a new possibility to modulate DC function.

Key Words: dendritic cells, CD83, hypusine, eIF-5A, nuclear export


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS